Calcium plus vitamin D supplementation during pregnancy interacts with polymorphisms in the promoter region of the VDR gene to affect postpartum bone mass of Brazilian adolescent mothers: A randomized controlled trial.
Study Goal
The researchers investigated whether calcium plus vitamin D supplementation interacts with VDR gene polymorphisms to affect postpartum bone mass changes in adolescent mothers.
Results Summary
Calcium plus vitamin D supplementation minimized postpartum bone loss, particularly in adolescents with specific VDR gene genotypes (1521 GG/1012 AA), while placebo group mothers with these genotypes showed greater bone loss. The supplemented group had different changes in serum 25(OH)D compared to placebo.
Population
Pregnant Brazilian adolescents (14-19 years old).
Effective Dosage
600 mg/d calcium + 200 IU/d cholecalciferol.
Duration
From 26 weeks of pregnancy until parturition.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
calcium plus cholecalciferol (600 mg/d + 200 IU/d) | neutral | maternal bone mass | Brazilian adolescent mothers | - | interacted with polymorphisms in the VDR gene promoter region to affect changes on maternal bone mass | #1 |
calcium plus cholecalciferol (600 mg/d + 200 IU/d) | neutral | changes in serum 25(OH)D from pregnancy to postpartum | mothers carrying 1521 GG/1012 AA genotypes | - | differed between supplemented and placebo groups for mothers carrying 1521 GG/1012 AA genotypes | #2 |
placebo | decrease | total BMD z score | mothers carrying 1521 GG/1012 AA | - | had greater reduction | #3 |
placebo | decrease | femoral neck BMC | mothers carrying 1521 GG/1012 AA | - | had greater reduction | #4 |
placebo | decrease | femoral neck BMD | mothers carrying 1521 GG/1012 AA | - | had greater reduction | #5 |
placebo | decrease | total hip BA | adolescents with 1521 GG/1012 AA | - | decreased | #6 |
placebo | increase | total hip BA | adolescents with 1521 GC/1012 AG | - | increased | #7 |
calcium plus vitamin D supplementation | neutral | postpartum bone loss | - | - | interacted with polymorphisms in the VDR gene promoter region affecting postpartum bone loss | #8 |
calcium plus vitamin D supplementation | decrease | postpartum bone loss | adolescents with 1521 GG/1012 AA | - | appeared to minimize postpartum bone loss | #9 |
OBJECTIVE: We investigated whether calcium plus vitamin D supplementation interacts with polymorphisms in the VDR gene promoter region to affect changes on maternal bone mass from 5 to 20 wk postpartum in Brazilian adolescent mothers. METHODS: Pregnant adolescents (14-19 y) randomly received calcium plus cholecalciferol (600 mg/d + 200 IU/d, n = 30) or placebo (n = 26) from 26 wk of pregnancy until parturition. Bone mineral content (BMC), bone area (BA), and bone mineral density (BMD) at total body, lumbar spine, total hip, and femoral neck were evaluated at 5 and 20 wk postpartum. Serum 25-hydroxyvitamin D (25[OH]D) and parathyroid hormone concentrations were measured. Real-time polymerase chain reaction was used for genotyping rs7139166 (1521 pb G > C) and rs4516035 (1012 pb A > G). Interactions between supplementation and polymorphisms were adjusted for significant covariates. RESULTS: Changes in serum 25(OH)D from pregnancy to postpartum differed between supplemented and placebo groups for mothers carrying 1521 GG/1012 AA genotypes (P = 0.004). Only in the placebo group, mothers carrying 1521 GG/1012 AA had greater reduction in total BMD z score, femoral neck BMC, and BMD from 5 to 20 wk postpartum compared with those with 1521 GC/1012 AG (P < 0.05). In the placebo group, total hip BA decreased from 5 to 20 wk postpartum in adolescents with 1521 GG/1012 AA, but increased in those with 1521 GC/1012 AG (P < 0.05), in contrast to the supplemented group. CONCLUSION: Calcium plus vitamin D supplementation during pregnancy interacted with polymorphisms in the VDR gene promoter region affecting postpartum bone loss. The increased supply of calcium and vitamin D appeared to minimize postpartum bone loss particularly in adolescents with 1521 GG/1012 AA.